Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Free Cash Flow (2016 - 2025)

Abeona Therapeutics (ABEO) has 15 years of Free Cash Flow data on record, last reported at -$26.6 million in Q3 2025.

  • For Q3 2025, Free Cash Flow fell 143.02% year-over-year to -$26.6 million; the TTM value through Sep 2025 reached -$84.0 million, down 71.87%, while the annual FY2024 figure was -$58.5 million, 56.56% down from the prior year.
  • Free Cash Flow reached -$26.6 million in Q3 2025 per ABEO's latest filing, down from -$18.7 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$5.8 million in Q3 2023 and bottomed at -$33.5 million in Q4 2021.
  • Average Free Cash Flow over 5 years is -$14.4 million, with a median of -$13.4 million recorded in 2024.
  • Peak YoY movement for Free Cash Flow: tumbled 1939.26% in 2021, then soared 58.16% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at -$33.5 million in 2021, then skyrocketed by 58.16% to -$14.0 million in 2022, then surged by 33.85% to -$9.3 million in 2023, then tumbled by 103.18% to -$18.8 million in 2024, then crashed by 41.44% to -$26.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$26.6 million in Q3 2025, -$18.7 million in Q2 2025, and -$19.8 million in Q1 2025.